COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Geert R. D'Haens  ¹     Walter Reinisch  ²     Stefan Schreiber  ³     Fraser Cummings  ⁴     Peter Irving  ⁵     Byong Duk Ye  ⁶     Dong-Hyeon Kim  ⁷     Sangwook Yoon     Shomron Ben-Horin  ^8    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
² Medical University of Vienna, Vienna, Austria
³ University Hospital Schleswig-Holstein, Kiel, Germany
⁴ University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
⁵ Guy’s and St Thomas’ Hospital, London, United Kingdom
⁶ University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of
⁷ Celltrion Healthcare, Incheon, Korea, Republic of
⁸ Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)